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140a Sunday, February 26, 2012fibrosis and CD31 immunostaining for cardiac angiogenesis were performed. A
p<0.05 was considered significant. Values were mean5SE. LP was associated
with heart hypertrophy (p<0.05 vs. NP) that was reversed 7-days PP (heart
weight: NP=12053, LP= 16352, PP1= 14552, PP7= 11751 mg). Con-
versely, heart weight/body weight (hw/bw) ratio was decreased in LP
(p<0.05 vs. NP) that was reversed in PP1 (hw/bw: NP=5.950.1, LP=
4.550.1, PP1= 5.650.1). LV ejection fraction was reduced in LP (p<0.05
vs. NP) and was also restored at PP1 (NP=7454, LP= 5751, PP1=
7351%). Cardiac angiogenesis was significantly increased in LP (p<0.001
vs. NP), and was fully restored in PP7 (p<0.001 vs. LP) (Capillary density:
NP=0.9550.01, LP=1.2550.02, PP7=0.9850.01 capillaries/myocyte). Simi-
larly, VEGF was upregulated in LP, and was restored in PP7 (NP=150.1,
LP=1.4 50.1, PP7=0.8350.1). There was no increase in cardiac fibrosis
in pregnancy-induced heart hypertrophy. Transcript levels of extracellular
matrix (ECM) degrading enzyme MMP2 were downregulated in LP (p<0.05
vs. NP) and were restored at 7-days PP (NP=150.01, LP=0.4750.03,
PP7=0.7050.1). In conclusion, pregnancy-induced heart hypertrophy is asso-
ciated with increased cardiac angiogenesis, lack of fibrosis, decreased MMP2
and decreased diastolic function of the heart that are reversed postpartum.
We speculate that physiologic heart hypertrophy of pregnancy has minimal
cardiac ECM remodeling.
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tension in Rats and Inhibits Human Pulmonary Artery Smooth Muscle
Cell Proliferation In Vitro
Soban Umar, Rangarajan D. Nadadur, Katharina S. Volz, Reza Foroughi,
Mansoureh Eghbali.
Univ of California, Los Angeles, Los Angeles, CA, USA.
Pulmonary hypertension (PH) is a characterized by arterial obstruction result-
ing from proliferation of pulmonary artery smooth muscle and endothelial cells.
Genetic deletion of apolipoprotein-A1 increases airway hyperresponsiveness,
inflammation, and collagen deposition in the lung. Apolipoprotein-A1 mimetic
peptide 4F protects endothelial function, causes vasodilation, decreases inflam-
mation and oxidative stress in lungs, yet its role in treating PH and right ven-
tricular (RV) dysfunction is not known. We hypothesized that 4F may rescue
pre-existing severe PH. We also investigate the effects of 4F on human pulmo-
nary artery smooth muscle cell (hPASMC) proliferation in vitro as a possible
mechanism of rescue by 4F. Twenty three rats were randomly divided into
4-groups. PH was induced by monocrotaline (MCT, 60mg/kg, s.c.). Severe
PH was well-established at day-21 (PH, n=6) that progressed to RV failure
(RVF, n=6) by day-30. One MCT-group was treated with 4F (50mg/kg/day,
s.c., n=6) from day-21 to 30. Saline-treated rats served as control (CTRL,
n=5). Serial echocardiography was performed to monitor cardiopulmonary he-
modynamics. Cardiac catheterization was performed terminally to record RV-
pressure (RVP). hPASMCs proliferation was assessed by MTT-assay. p<0.05
was considered significant. Values were mean5SE. Rats developed severe
PH 21-days after MCT (RVP=67.1251 vs. 29.851 mmHg in CTRL, RV/
LVþIVS= 0.6550.05 vs. 0.2350.02, RV-ejection fraction (RVEF)= 4051
vs. 6551%, all p<0.05 vs. CTRL), which progressed to RVF by day-30
[RVP=7451; RV/(LVþIVS)=0.6850.05; RVEF=28.651%, p<0.05 for all
vs. CTRL]. 4F-therapy from day-21 to 30 resulted in rescue of PH
(RVP=4753 mmHg, RV/LVþIVS= 0.3850.02, RVEF= 51.753%, p<0.05
vs. PH and RVF). 4F also inhibited hPASMC proliferation (~60% inhibition
at 100ng 4F/ml medium, p<0.05). In conclusion, 4F rescues pre-existing severe
PH and RV-dysfunction. Inhibition of PASMC proliferation may be one of the
key mechanisms in this rescue.
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Pulmonary Hypertension (PH) is a disease of increasing pulmonary arterial
pressure characterized by extensive lung inflammation and fibrosis. We have
previously shown that Genistein, a soy isoflavone, can rescue severe PH. Since
Genistein is a selective Estrogen Receptor Beta agonist, here we examined
whether Genistein can reverse fibrosis and inflammation induced by PH via
an Estrogen Receptor Beta dependent mechanism. PH was established by treat-
ing male rats with monocrotaline (MCT, 60mg/kg, s.c.). At day 21 when severe
PH was established, rats were treated with 10 day Genistein therapy (Gen
group), Genistein therapy in the presence of selective Estrogen Receptor
b antagonist PHTPP (GenþPHTPP group), or were left untreated to develop
right ventricular failure (RVF group). RVF animals developed severe pulmo-nary hypertension (RVP=72.9651.39mmHg vs 31.1550.56 mmHg in
CTRL; RVEF=28.7650.79% vs 66.2251.40% in CTRL, all p<.05). Genis-
tein therapy restored these abnormalities (RVEF=65.6751.08%, RVP ¼
43.3454.08 mmHg, p<0.05 vs RVF). Interestingly, in the presence of
Estrogen Receptor Beta antagonist PHTPP, Genistein failed to rescue these
animals (RVP=61.2254.40, RVEF=42.2752.7%, p=n.s. vs RVF). Masson’s
Trichrome staining revealed extensive lung fibrosis in RVF group, which
was also restored with Gen therapy. Again, GenþPHTPP group showed no
reversal of pulmonary fibrosis. Immunoperoxidase staining showed an increase
in ED-1 positive cells in the lung of RVF-group indicating increased inflamma-
tion. This change was reversed entirely by Genistein therapy. RT PCR also
revealed that pro-inflammatory molecules TNFa and IL-1b were both elevated
more than 2-fold in the lung of RVF animals and reversed with Genistein
therapy (all p<0.05). Interestingly, GenþPHTPP animals still showed signifi-
cantly elevated ED-1 positive cells in the lung as well as elevated TNFa and
IL1b (all p=n.s. vs RVF). These results suggest that genistein induced reversal
of lung inflammation and fibrosis during pulmonary hypertension is mediated
through Estrogen Receptor b.
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Heart failure is generally characterized by increased fibrosis and inflammation,
which lead to functional and contractile defects. Recently we discovered that
estrogen (E2) therapy can rescue advanced heart failure (HF) induced by pres-
sure overload in mice by restoring left ventricular (LV) pressure and function.
Here, we investigate the effects of E2 on reversing the adverse remodeling of
the LV occurring during HF. Trans-aortic constriction procedure was used
to induce HF. Once the ejection fraction reached ~30%, one group of
mice was sacrificed and the other group was treated with E2 (30 mg/kg/day)
for 10 days. In vitro, co-cultured neonatal rat ventricular myocytes and
fibroblasts were treated with angiotensin II (AngII) in the presence or absence
of E2. Quantitative real-time PCR showed that the transcript levels of the pro-
fibrotic markers collagen I, TGFb, fibrosin 1 (FBRS) and lysil oxidase (LOX)
were significantly upregulated in HF (from 1.0050.16 to 1.8350.11for
collagen 1, 1.0050.86 to 4.3350.59 for TGFb, 1.0050.52 to 3.6150.22
for FBRS and 1.0050.33 to 2.8850.32 for LOX) and were reduced with E2
treatment to levels similar to CTRL. In vitro studies validated our in vivo find-
ings, as E2 also restored AngII-induced upregulation of LOX and TGFb from
6.8750.26 in AngII to 2.8051.5 in AngIIþE2 and 3.3050.25 to 1.5950.21
in AngIIþE2, respectively (values normalized to CTRL). Furthermore, the pro-
inflammatory interleukins IL-1b and IL-6 were upregulated from 1.0050.19 to
1.9050.09 and 1.0050.30 to 5.2950.77 in HF, respectively, and reversed to
CTRL levels with E2 therapy. The anti-inflammatory interleukin IL-10 was
downregulated from 1.0050.17 to 0.4950.03 in HF and reversed to
0.6750.09 with E2 treatment. This data strongly suggests that one of the mech-
anisms for the beneficial action of estrogen on left ventricular heart failure is
through reversal of inflammation and fibrosis.
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Pulmonary hypertension (PH) leads to right-ventricular hypertrophy and failure
(RVF). RVF involves adverse remodeling of the ventricular extracellular
matrix (ECM). Recently we found that estrogen (E2) rescues PH-induced
RVF. Here we explore whether the rapid restoration of RV function by E2 ther-
apy during PH-induced RVF is in part due to a direct effect of E2 on the adverse
ECM remodeling of the RV. In vivo, rats were injected with monocrotaline. At
day 21, when PH had established, rats either received E2 (E2-group) for 10
days or were left untreated to develop RVF (RVF-group). In vitro, co-
cultured neonatal rat ventricular myocytes and fibroblasts were treated with
Angiotensin II in the presence or absence of E2 (AngII and AngIIþE2 resp.).
In vivo, E2 reversed RV fibrosis (4.0650.52% in CTRL, 3353.2 in RVF,
5.6650.33% in E2 group, all P<.05). In vitro, E2 similarly inhibited AngII in-
duced increase in Collagen I transcript in cultured myocytes and fibroblasts
(1.4950.04 in AngII, 0.7550.04 in AngIIþE2, normalized to CTRL,
p<.05). In vivo, E2 reversed PH induced increases of ECM remodeling en-
zymes OPN, ADAM15 and ADAM17 in the RV (9.3352.07 in RVF,
0.4550.16 in E2 for OPN; 2.1350.19 in RVF, 0.4750.07 in E2 for
